SCHEMBL29600076

SCHEMBL29600076

CC1(c2ccc(CCC(=O)O)s2)OCCO1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.43
ALDH1A1 P00352 1/20 0.43
PRNP P04156 1/20 0.43
RECQL P46063 1/20 0.43
RXFP1 Q9HBX9 1/20 0.43
CYP26A1 O43174 3/20 0.40
CYP26B1 Q9NR63 3/20 0.40
RPS6KB2 Q9UBS0 2/20 0.39
POLB P06746 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
FFAR1 O14842 7/20 0.36
RXRA P19793 1/20 0.34
KEAP1 Q14145 1/20 0.34
FFAR4 Q5NUL3 1/20 0.34
L3MBTL1 Q9Y468 2/20 0.33
PKM P14618 1/20 0.33
HPGD P15428 1/20 0.33
TSHR P16473 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1705828 0.84 HPGD (0.41) LMNAALDH1A1PRNPRECQLRXFP1
SCHEMBL855028 0.76 MEN1 (0.37) ALDH1A1HPGD
SCHEMBL29599997 0.76 PRSS1 (0.41) ALDH1A1RECQLPOLBRXRAL3MBTL1
SCHEMBL9169334 0.75 RPS6KB2 (0.51) LMNAALDH1A1PRNPRECQLRXFP1
SCHEMBL29599669 0.75 CYP26A1 (0.40) LMNAALDH1A1PRNPRECQLRXFP1
SCHEMBL29599886 0.75 HDAC6 (0.37) LMNAALDH1A1PRNPRECQLRXFP1
SCHEMBL4632230 0.74 NPC1 (0.51) LMNAALDH1A1PRNPRECQLRXFP1
SCHEMBL855952 0.73 CYP2E1 (0.36) CYP3A4
SCHEMBL856231 0.73
SCHEMBL29599237 0.73 CYP26B1 (0.41) CYP26A1CYP26B1FFAR1RXRATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12552757-B2 NRF2-activating compound SENJU PHARMACEUTICAL CO., LTD. (JP) 2026-02-17 US disclosed
US-20240132519-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2024-04-25 US disclosed
EP-4273145-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2023-11-08 EP disclosed
US-20230024995-A1 NRF2-ACTIVATING COMPOUND SENJU PHARMACEUTICAL CO., LTD. (JP) 2023-01-26 US disclosed
EP-3998262-A1 NRF2-ACTIVATING COMPOUND Senju Pharmaceutical Co., Ltd. (JP) 2022-05-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230024995-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 LMNA 2078/4885ALDH1A1 555/4885PRNP 2624/4885
US-12552757-B2 NRF2-activating compound NFE2L2, NFE2, KEAP1 LMNA 3058/4885ALDH1A1 790/4885PRNP 3094/4885
US-20240132519-A1 NRF2-ACTIVATING COMPOUND NFE2L2, KEAP1, NFE2 LMNA 2635/4885ALDH1A1 756/4885PRNP 3920/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.